JP2014509851A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509851A5
JP2014509851A5 JP2013557704A JP2013557704A JP2014509851A5 JP 2014509851 A5 JP2014509851 A5 JP 2014509851A5 JP 2013557704 A JP2013557704 A JP 2013557704A JP 2013557704 A JP2013557704 A JP 2013557704A JP 2014509851 A5 JP2014509851 A5 JP 2014509851A5
Authority
JP
Japan
Prior art keywords
npp1
fusion protein
npp1 fusion
acid residues
targeting moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013557704A
Other languages
English (en)
Japanese (ja)
Other versions
JP5735665B2 (ja
JP2014509851A (ja
Filing date
Publication date
Priority claimed from PCT/US2011/028233 external-priority patent/WO2011113027A2/en
Application filed filed Critical
Priority claimed from PCT/US2011/051858 external-priority patent/WO2012125182A1/en
Publication of JP2014509851A publication Critical patent/JP2014509851A/ja
Publication of JP2014509851A5 publication Critical patent/JP2014509851A5/ja
Application granted granted Critical
Publication of JP5735665B2 publication Critical patent/JP5735665B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013557704A 2010-03-12 2011-09-15 Npp1融合タンパク質 Active JP5735665B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34006610P 2010-03-12 2010-03-12
USPCT/US2011/028233 2011-03-11
PCT/US2011/028233 WO2011113027A2 (en) 2010-03-12 2011-03-11 Npp1 fusion proteins
PCT/US2011/051858 WO2012125182A1 (en) 2011-03-11 2011-09-15 Npp1 fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015084216A Division JP6096826B2 (ja) 2010-03-12 2015-04-16 Npp1融合タンパク質

Publications (3)

Publication Number Publication Date
JP2014509851A JP2014509851A (ja) 2014-04-24
JP2014509851A5 true JP2014509851A5 (cg-RX-API-DMAC7.html) 2014-11-06
JP5735665B2 JP5735665B2 (ja) 2015-06-17

Family

ID=44564171

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013557704A Active JP5735665B2 (ja) 2010-03-12 2011-09-15 Npp1融合タンパク質
JP2015084216A Active JP6096826B2 (ja) 2010-03-12 2015-04-16 Npp1融合タンパク質
JP2017026961A Active JP6484905B2 (ja) 2010-03-12 2017-02-16 Npp1融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015084216A Active JP6096826B2 (ja) 2010-03-12 2015-04-16 Npp1融合タンパク質
JP2017026961A Active JP6484905B2 (ja) 2010-03-12 2017-02-16 Npp1融合タンパク質

Country Status (10)

Country Link
US (7) US8846603B2 (cg-RX-API-DMAC7.html)
EP (1) EP2545080B1 (cg-RX-API-DMAC7.html)
JP (3) JP5735665B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013023010B1 (cg-RX-API-DMAC7.html)
CL (1) CL2013002607A1 (cg-RX-API-DMAC7.html)
ES (2) ES2628841T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ615070A (cg-RX-API-DMAC7.html)
SG (2) SG10201500208SA (cg-RX-API-DMAC7.html)
TR (1) TR201903573T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011113027A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
NZ715014A (en) 2010-09-09 2018-10-26 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
AU2011362576B2 (en) * 2011-03-11 2017-06-08 Alexion Pharmaceuticals, Inc. NPP1 fusion proteins
EP2956163B1 (en) 2013-02-13 2024-11-27 Yale University Compositions for treating pathological calcification and ossification
JP6514190B2 (ja) * 2013-05-06 2019-05-15 バイオ−ラッド ラボラトリーズ インコーポレーティッド 参照物質における不安定な被分析物の安定化
BR112017012928A2 (pt) 2014-12-19 2018-05-15 Alexion Pharma Inc uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste
CA3176123A1 (en) * 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
JP2018537093A (ja) 2015-11-20 2018-12-20 イエール ユニバーシティ 異所性石灰化障害を治療するための組成物およびそれを使用する方法
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
BR112019002355A2 (pt) 2016-08-05 2019-07-16 Yale University composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
WO2019067502A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE
CN112930397B (zh) * 2018-08-31 2025-05-09 耶鲁大学 Enpp1多肽及其使用方法
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
WO2025184419A1 (en) * 2024-02-29 2025-09-04 Kodiak Sciences Inc. Engineered complement inhibitor proteins

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
DE69842019D1 (de) 1997-10-16 2011-01-05 Synageva Biopharma Corp Transgene vögel und proteinproduktion
ES2260852T3 (es) 1997-11-07 2006-11-01 Trillium Therapeutics Inc. Metodos y composiciones para inmunomodulacion.
DE20121960U1 (de) 2000-04-06 2004-01-15 Epigenomics Ag Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten
US20020108132A1 (en) 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
SI2348114T1 (sl) 2004-04-21 2018-11-30 Alexion Pharmaceuticals, Inc. Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti
WO2006031994A2 (en) * 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US20090180989A1 (en) * 2005-10-05 2009-07-16 Synageva Biopharma Corp. Compositions and methods for delivering nucleotide sequences to vertebrates
JP5732603B2 (ja) 2007-05-11 2015-06-10 アレクション ファーマ ホールディング 骨標的アルカリホスファターゼ、キット及びその使用方法
AR071885A1 (es) * 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins

Similar Documents

Publication Publication Date Title
JP2014509851A5 (cg-RX-API-DMAC7.html)
ES2342669T3 (es) Adzimas y usos de las mismas.
JP2005120106A5 (cg-RX-API-DMAC7.html)
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
JP2012531208A5 (cg-RX-API-DMAC7.html)
JP2012522501A5 (cg-RX-API-DMAC7.html)
JP2016527891A5 (cg-RX-API-DMAC7.html)
NZ615070A (en) Npp1 fusion proteins
JP2015525217A5 (cg-RX-API-DMAC7.html)
HRP20161531T1 (hr) Fc fuzijski proteini koji sadrže nove linkere ili aranžmane
JP2017018125A5 (cg-RX-API-DMAC7.html)
JP2015212284A5 (cg-RX-API-DMAC7.html)
RU2018117558A (ru) Слитые иммуномодулирующие белки и способы их получения
RS64002B1 (sr) Anti-kancerski fuzioni polipeptid
JP2010273685A5 (cg-RX-API-DMAC7.html)
JP2019527200A5 (cg-RX-API-DMAC7.html)
JP2008301828A5 (cg-RX-API-DMAC7.html)
JP2014510518A5 (cg-RX-API-DMAC7.html)
FI2968461T3 (fi) Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi
HRP20221531T1 (hr) Pripravci faktora viii i postupci dobivanja i korištenja istih
JP2017512063A5 (cg-RX-API-DMAC7.html)
JP2012095652A5 (cg-RX-API-DMAC7.html)
JP2011501971A5 (cg-RX-API-DMAC7.html)
RU2011144569A (ru) Мутанты индуцируемой активацией цитидиндеаминазы (aid) и способы их применения
JP2008536479A5 (cg-RX-API-DMAC7.html)